Vaxil Bio Ltd
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. Its lead product candidate is ImMucin, a MUC1 SP-based vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. The company is headquartered in Toronto, Canada.
Vaxil Bio Ltd (VXLLF) - Net Assets
Latest net assets as of September 2025: $667.00K USD
Based on the latest financial reports, Vaxil Bio Ltd (VXLLF) has net assets worth $667.00K USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($675.00K) and total liabilities ($8.00K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $667.00K |
| % of Total Assets | 98.81% |
| Annual Growth Rate | N/A |
| 5-Year Change | -10.95% |
| 10-Year Change | N/A |
| Growth Volatility | 112.94 |
Vaxil Bio Ltd - Net Assets Trend (2013–2024)
This chart illustrates how Vaxil Bio Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Vaxil Bio Ltd (2013–2024)
The table below shows the annual net assets of Vaxil Bio Ltd from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $716.00K | -19.64% |
| 2023-12-31 | $891.00K | -21.57% |
| 2022-12-31 | $1.14 Million | -33.18% |
| 2021-12-31 | $1.70 Million | +111.44% |
| 2020-12-31 | $804.00K | +237.91% |
| 2019-12-31 | $-583.00K | -234.02% |
| 2018-12-31 | $435.00K | +189.32% |
| 2017-12-31 | $-487.00K | -174.24% |
| 2016-12-31 | $656.00K | +402.30% |
| 2015-12-31 | $-217.00K | +54.40% |
| 2014-12-31 | $-475.86K | +14.26% |
| 2013-12-31 | $-555.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vaxil Bio Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 36000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $20.25 Million | 2828.35% |
| Total Equity | $716.00K | 100.00% |
Vaxil Bio Ltd Competitors by Market Cap
The table below lists competitors of Vaxil Bio Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Weaccess Group SA
PA:MLWEA
|
$20.69K |
|
EFC (I) Limited
NSE:EFCIL
|
$20.72K |
|
Vitru Brasil Empreendimentos, Participações e Comércio S.A.
SA:VTRU3
|
$20.73K |
|
D&D Platform Reit Co Ltd
KO:377190
|
$20.74K |
|
ABC MOTORS COMPANY LTD
SEM:ABC
|
$20.66K |
|
LI NING
MU:LNLB
|
$20.65K |
|
YAHOO JAPAN - Dusseldorf Stock Exchang
DU:YOJ
|
$20.63K |
|
Liontrust Asset Management
LSE:LIO
|
$20.57K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vaxil Bio Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 891,000 to 716,000, a change of -175,000 (-19.6%).
- Net loss of 178,000 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-178.00K | -24.86% |
| Other Changes | $3.00K | +0.42% |
| Total Change | $- | -19.64% |
Book Value vs Market Value Analysis
This analysis compares Vaxil Bio Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.03x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-0.01 | $0.01 | x |
| 2018-12-31 | $0.00 | $0.01 | x |
| 2019-12-31 | $-0.01 | $0.01 | x |
| 2020-12-31 | $0.01 | $0.01 | x |
| 2021-12-31 | $0.01 | $0.01 | x |
| 2022-12-31 | $0.01 | $0.01 | x |
| 2023-12-31 | $0.33 | $0.01 | x |
| 2024-12-31 | $0.26 | $0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vaxil Bio Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -24.86%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.02x
- Recent ROE (-24.86%) is above the historical average (-105.36%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.58 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.55 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.05 Million |
| 2016 | -691.92% | 0.00% | 0.00x | 1.86x | $-4.60 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.75 Million |
| 2018 | -240.69% | 0.00% | 0.00x | 2.05x | $-1.09 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.10 Million |
| 2020 | -168.91% | 0.00% | 0.00x | 2.07x | $-1.44 Million |
| 2021 | -58.00% | 0.00% | 0.00x | 1.34x | $-1.16 Million |
| 2022 | -51.41% | 0.00% | 0.00x | 1.36x | $-697.60K |
| 2023 | -28.51% | 0.00% | 0.00x | 1.10x | $-343.10K |
| 2024 | -24.86% | 0.00% | 0.00x | 1.02x | $-249.60K |
Industry Comparison
This section compares Vaxil Bio Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vaxil Bio Ltd (VXLLF) | $667.00K | 0.00% | 0.01x | $20.69K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |